Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

This trial tests whether an investigational drug called HDM1005, given as a weekly injection, can help people with obstructive sleep apnea and obesity. Participants will receive either HDM1005 or a placebo for 52 weeks, alongside lifestyle counseling on diet and physical activity…

This phase 3 trial is testing whether an investigational drug called HDM1005, given as a once-weekly injection, can improve obstructive sleep apnea and reduce body weight in people with obesity who do not use positive airway pressure (PAP) therapy. About 200 adults aged 18 to 75 …

This trial tests whether a once-daily foam containing roflumilast can treat seborrheic dermatitis, a common skin condition causing red, flaky patches on the scalp, face, and trunk. About 300 people ages 9 and older with moderate to severe disease will apply either the active foam…

This clinical trial is testing whether adding an experimental drug called HDM2005 to a standard treatment (rituximab and lenalidomide) can help people with mantle cell lymphoma whose cancer has returned or not responded to previous therapies. The study involves about 40 adults an…

This study tests a new drug called HDM2017 combined with standard treatment (fruquintinib) in 120 people with advanced colorectal cancer that has spread. The goal is to find the safest dose and see if the combination can shrink tumors. Participants must have tried other treatment…

This study tests whether a new drug, HDM1005, works better than another drug called mazdutide at controlling blood sugar in people with type 2 diabetes. About 912 adults whose diabetes is not well controlled with metformin (alone or with another diabetes pill) will receive one of…

This study tests whether adding ganagliflozin tablets to standard care can slow kidney disease progression in 1,244 adults with type 2 diabetes and chronic kidney disease. Participants will take either ganagliflozin or a placebo daily for 120 weeks. The main goal is to measure ch…

This early study will test a single dose of the experimental drug HDM1005 in 30 overweight or obese adults, some with moderate or severe kidney disease and some with healthy kidneys. The goal is to see how kidney function affects the drug's levels in the body and to check for saf…

This early-stage study will test an experimental drug called HDM1005 in 42 overweight or obese adults. Researchers want to see how HDM1005 affects stomach emptying and whether it changes how the body processes common medications like metformin, atorvastatin, warfarin, and digoxin…